You are here

  • Home
  • Archive
  • Volume 4, Issue 2
  • Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study

Article metrics

Article menu
XML
Health policy
Research
Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study

 

Online download statistics by month:

Online download statistics by month: January 2018 to April 2024

AbstractFullPdf
Jan 201822165
Feb 201825173
Mar 201833225
Apr 201816140
May 201825132
Jun 201835191
Jul 20181970
Aug 201832242
Sep 201824223
Oct 201823216
Nov 201812123
Dec 2018774
Jan 2019883
Feb 201931323
Mar 201913138
Apr 201913127
May 2019875
Jun 201911116
Jul 2019111110
Aug 2019664
Oct 201920182
Nov 2019553
Dec 2019881
Jan 2020775
Feb 202010102
Mar 202024164
May 20201297
Jun 2020881
Jul 2020751
Aug 20201284
Sep 202012100
Oct 202014147
Nov 202025219
Dec 202011112
Jan 202111103
Feb 202110104
Mar 202127255
Apr 202129241
May 202116167
Jun 202119192
Jul 2021881
Aug 2021883
Sep 20211097
Oct 2021171421
Nov 20216614
Dec 20211396
Jan 202217181
Feb 202227303
Mar 202221212
Apr 202230294
May 2022242211
Jun 202210102
Jul 202218172
Aug 202214148
Sep 20221073
Oct 202217177
Nov 202211108
Dec 2022880
Jan 202316158
Feb 202315123
Mar 20231082
Apr 202318199
May 202312810
Jun 202315111
Jul 20239914
Aug 202318196
Sep 202310101
Oct 20231385
Nov 202315154
Dec 202329215
Jan 2024882
Feb 20241081
Mar 20242523102
Apr 2024201619
Total11731015445